# Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation

> **NCT07418138** · — · COMPLETED · sponsor: **Hu Liangshuo** · enrollment: 484 (actual)

## Conditions studied

- Liver Transplantation
- Hepatocellular Carcinoma (HCC)
- Tyrosine Kinase Inhibitor
- Survival Rate

## Interventions

- **OTHER:** Medication history
- **OTHER:** Medication history

## Key facts

- **NCT ID:** NCT07418138
- **Lead sponsor:** Hu Liangshuo
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 484 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07418138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07418138, "Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07418138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*